pyrazines has been researched along with Ph 1 Chromosome in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Levy, Y; Maisel, C; Robinson, S; Tong, AW | 1 |
| Imai, K | 1 |
| Cho, DJ; Kim, DW; Kim, SH; Lee, JI; Noh, H; Oh, SJ; Park, HL; Park, MS; Zang, DY | 1 |
| Chen, ST; Dewar, R; Khosravi-Far, R; Miller, K; Yeckes-Rodin, H | 1 |
| Chang, H; Gong, YP; Xing, HY; Yang, L; Yang, X; Zheng, BH; Zhou, RQ | 1 |
1 review(s) available for pyrazines and Ph 1 Chromosome
| Article | Year |
|---|---|
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult | 2014 |
1 trial(s) available for pyrazines and Ph 1 Chromosome
| Article | Year |
|---|---|
Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Body Surface Area; Body Weight; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Young Adult | 2016 |
3 other study(ies) available for pyrazines and Ph 1 Chromosome
| Article | Year |
|---|---|
Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Imidazoles; Male; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyridazines; Recurrence; Remission Induction | 2014 |
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Male; Middle Aged; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Remission Induction; Young Adult | 2011 |
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrimidines | 2010 |